← TrialMatch
HomeTrials

Cognitive Decline Following Deep Brain Stimulation

This research study aims to identify MRI-based brain biomarkers that predict an individual's response to Deep Brain Stimulation (DBS). In particular, this study will focus on changes in cognition associated with DBS. A total of 55 participants with Parkinson's Disease planning to undergo DBS will be recruited from MUSC

Condition(s)Parkinson Disease, Movement Disorders
StatusRecruiting
Study typeObservational
SummaryThis research study aims to identify MRI-based brain biomarkers that predict an individual's response to Deep Brain Stimulation (DBS). In particular, this study will focus on changes in cognition associated with DBS. A total of 55 participants with Parkinson's Disease planning to undergo DBS will be recruited from MUSCs Clinical DBS Program. Participants will undergo four visits, including a 1-hour screening visit, a 1.5-hour pre-DBS MRI scanning visit, and a 3.5-hour post-DBS cognitive assessment visit. In addition control participants without Parkinson's Disease will be recruited to undergo MRI scanning and cognitive assessments.
Who can participatePD Participants Inclusion Criteria: * Subjects above 18 years of age * Subjects who will undergo DBS surgery as part of their clinical care for PD Exclusion Criteria: * Uncorrected visual or hearing impairments, as indicated by self-report * Individuals who are pregnant or expect to become pregnant during the course of the study * Individuals with claustrophobia, or the inability to lie supine position in the MRI scanner * COPD with oxygen dependence * Non-MRI compatible metal implants (surgical clips or staples, cardiac pacemakers etc.) Non-PD Control Participants Inclusion Criteria: * Subjects above 18 years of age * Age matched to participants in PD group Exclusion Criteria: * Diagnosis of Parkinsons Disease or other movement disorder * Untreated neuropsychiatric disorders * Uncorrected
Ages18 Years
SexAll
Accepts healthy volunteersYes
Lead sponsorMedical University of South Carolina
LocationsCharleston, South Carolina, United States
Start date2023-04-01
NCT IDNCT05822388
Official listinghttps://clinicaltrials.gov/study/NCT05822388

🔍 Search all trials →